<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630602</url>
  </required_header>
  <id_info>
    <org_study_id>LODYN 4092</org_study_id>
    <nct_id>NCT02630602</nct_id>
  </id_info>
  <brief_title>Functional Goat Cheese Effect in Lipid Profile Change</brief_title>
  <acronym>LODYN</acronym>
  <official_title>Functional Goat Cheese Effect in Lipid Profile Change</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose this study was to evaluate the therapeutic effect of a functional goat cheese on&#xD;
      obese and overweight people with altered lipid profile. The functional goat cheese containing&#xD;
      polyunsaturated fatty acid, in amounts exceeding other cheese, was developed to benefit&#xD;
      cardiovascular health of people who need to normalize lipid profile; which in the long term&#xD;
      can contribute to the prevention of cardiovascular diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, parallel, double-blind, controlled is being performing to evaluate the effect&#xD;
      of a functional goat cheese on lipid profile in overweight or obese volunteers who need a&#xD;
      special diet.&#xD;
&#xD;
      Were included 60 volunteers (men and women) aged between 18 and 65 years (IMC ≥27&lt;40 Kg/m2)&#xD;
      with a cardiovascular risk (&lt;10%). The volunteers are being followed at La Paz University&#xD;
      Hospital of Madrid. For 12 weeks, the volunteers should consume 60 g of cheese daily&#xD;
      (functional cheese or control cheese) and to receive advice to follow a balanced and&#xD;
      individualized hypocaloric diet as well as physical activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline total cholesterol</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline Low density lipoprotein cholesterol</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline High density lipoprotein cholesterol</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline Triglycerides</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Apolipoprotein A1</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Apolipoprotein B</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Free fatty acids (FFA) in the plasma</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Erythrocyte membrane fatty acid composition</measure>
    <time_frame>0 and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Obesity and Overweight</condition>
  <arm_group>
    <arm_group_label>Functional goat cheese</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control cheese</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Functional goat cheese</intervention_name>
    <description>60 g per day during 12 weeks</description>
    <arm_group_label>Functional goat cheese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control cheese</intervention_name>
    <description>60 g per day during 12 weeks</description>
    <arm_group_label>Control cheese</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteers with overweight type II or obesity type I or II (IMC ≥27&lt;40 Kg/m2).&#xD;
&#xD;
          -  Cardiovascular risk &lt; 10% and almost two of follow factors:&#xD;
&#xD;
        Men ≥ 45 years old or women ≥ 55 years old; Familiar background of premature cardiovascular&#xD;
        disease; HDL cholesterol &lt;40 mg/dL for men and &lt;50 mg/dL for women; Total cholesterol ≥ 200&#xD;
        mg/dL; Triglycerides ≥ 150 mg/dL and &lt; 200 mg/dL; LDL ≥ 130 mg/dL and &lt; 160 mg/dL; Smoker&#xD;
&#xD;
          -  Accept advises to perform a balanced hypocaloric diet and regular practice of physical&#xD;
             activity.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with Diabetes Mellitus type 1;&#xD;
&#xD;
          -  Individuals with Diabetes Mellitus type 2, using medication;&#xD;
&#xD;
          -  Individuals with Dyslipidemia, using drug;&#xD;
&#xD;
          -  Individuals with high blood pressure, using medication;&#xD;
&#xD;
          -  Individuals with allergies to dairy protein;&#xD;
&#xD;
          -  Individuals with severe diseases (hepatic, kidney, cancer…);&#xD;
&#xD;
          -  Individuals with drugs or supplements consumption to weight lost;&#xD;
&#xD;
          -  Individuals that consume drugs, ω-3 supplements or supplement that can modify the&#xD;
             lipid and / or glucose profile (statins, fibrates, diuretics, corticosteroids,&#xD;
             insulin…);&#xD;
&#xD;
          -  Individuals who have participated in programs and / or clinical trials of weight&#xD;
             control in the last 6 months;&#xD;
&#xD;
          -  Individuals with increased alcohol consumption 30g/day;&#xD;
&#xD;
          -  Individuals that stop smoking in the next 20 weeks (during the study);&#xD;
&#xD;
          -  Individuals with mental disease or low cognitive function;&#xD;
&#xD;
          -  Pregnant women or breastfeeding;&#xD;
&#xD;
          -  Individuals with intensive physical activity;&#xD;
&#xD;
          -  Individuals with physical problems complying with the recommendations of physical&#xD;
             activity and diet general recommendations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gomez, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL LA PAZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

